NCT05561634 2025-09-30
RADIOSONIC
University Hospital, Lille
Phase 2 Recruiting
Clinical Trials
14 trialsNCT05463757 2025-04-04
Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
Maastricht University Medical Center
Recruiting
NCT02667574 2022-10-17
VISMONEO
University Hospital, Lille
Phase 2 Completed
NCT03610022 2022-08-18
OPTIVISMO-1
University Hospital, Bordeaux
Phase 4 Completed
NCT03035188 2022-02-11
NICCI
SRH Wald-Klinikum Gera GmbH
Phase 2 Completed
NCT02436408 2021-10-28
VISORB
University of Michigan Rogel Cancer Center
Phase 4 Completed
NCT01556009 2020-11-02
Vismodegib
UCSF Benioff Children's Hospital Oakland
Phase 2 Completed
NCT02956889 2020-01-29
virgilio
Istituto Clinico Humanitas
Phase 2 Terminated
NCT02067104 2019-08-14
Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention
University of Arizona
Phase 2 Terminated
NCT01700049 2019-05-23
Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes
Mayo Clinic
Phase 2 Completed
NCT02690948 2019-03-08
Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer
Stanford University
Phase 1/2 Completed
NCT02639117 2018-07-18
PDT-Vismo
University of Arizona
Phase 1 Completed
NCT01631331 2017-12-08
Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)
Stanford University
Phase EARLY_PHASE1 Completed
NCT01543581 2014-09-26
Erivedge
Loma Linda University
Phase 2 Completed